Future perspectives on the treatment of hepatocellular carcinoma with cisplatin.
about
Strategy for improving survival and reducing recurrence of HCV-related hepatocellular carcinomaPhase I study of miriplatin combined with transarterial chemotherapy using CDDP powder in patients with hepatocellular carcinoma.A Phase I/II trial of continuous hepatic intra-arterial infusion of 5-fluorouracil, mitoxantrone and cisplatin for advanced hepatocellular carcinoma.Transhepatic arterial infusion chemotherapy using a combination of miriplatin and CDDP powder versus miriplatin alone in the treatment of hepatocellular carcinoma: a randomized controlled trial.RYBP expression is associated with better survival of patients with hepatocellular carcinoma (HCC) and responsiveness to chemotherapy of HCC cells in vitro and in vivo.The Ethanolic Extract of Taiwanofungus camphoratus (Antrodia camphorata) Induces Cell Cycle Arrest and Enhances Cytotoxicity of Cisplatin and Doxorubicin on Human Hepatocellular Carcinoma Cells.Comparison of the efficacy of transcatheter arterial chemoembolization and sorafenib for advanced hepatocellular carcinomaProtein phosphatase 2A-B55δ enhances chemotherapy sensitivity of human hepatocellular carcinoma under the regulation of microRNA-133b.Hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma in Japan.MAPK signaling in cisplatin-induced death: predominant role of ERK1 over ERK2 in human hepatocellular carcinoma cells.Long noncoding RNA HULC modulates the phosphorylation of YB-1 through serving as a scaffold of extracellular signal-regulated kinase and YB-1 to enhance hepatocarcinogenesis.Effect of double platinum agents, combination of miriplatin-transarterial oily chemoembolization and cisplatin-hepatic arterial infusion chemotherapy, in patients with hepatocellular carcinoma: Report of two casesFermented wheat germ extract induced cell death and enhanced cytotoxicity of Cisplatin and 5-Fluorouracil on human hepatocellular carcinoma cells.
P2860
Q27023495-E9668466-2FCC-4816-9C2C-82C827979E28Q31096586-00E2DC91-571D-4464-93D7-D414B82847FAQ33440349-492D5713-A0E9-4DCB-B388-9FD8F1A09E72Q33660203-0B106209-2A5E-48BC-9138-67A7CB309E84Q34956767-0B2609A9-42F0-48E9-8E58-F67D50713E0DQ36236520-412F05A0-CA2F-4BBC-9819-28A4CFBAC498Q36415924-1294D544-2B77-42FE-B300-1C723D46F4D1Q36796805-C13BA6A2-D749-49CE-90BE-10CEF4F39344Q38161384-E0AC5ECC-6638-47F1-969B-B745107EA228Q39264596-823D4740-B4ED-413A-BD24-22236F4B04FBQ40405868-E1C3A3ED-D79D-433F-8A67-405A90F1792FQ41072005-95D7F5E9-2246-4986-9CEE-3554FC5C05D9Q41852076-B499C6E5-E697-4B61-84D2-6767DE562535
P2860
Future perspectives on the treatment of hepatocellular carcinoma with cisplatin.
description
2009 nî lūn-bûn
@nan
2009 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年学术文章
@wuu
2009年学术文章
@zh-cn
2009年学术文章
@zh-hans
2009年学术文章
@zh-my
2009年学术文章
@zh-sg
2009年學術文章
@yue
name
Future perspectives on the treatment of hepatocellular carcinoma with cisplatin.
@ast
Future perspectives on the treatment of hepatocellular carcinoma with cisplatin.
@en
Future perspectives on the treatment of hepatocellular carcinoma with cisplatin.
@nl
type
label
Future perspectives on the treatment of hepatocellular carcinoma with cisplatin.
@ast
Future perspectives on the treatment of hepatocellular carcinoma with cisplatin.
@en
Future perspectives on the treatment of hepatocellular carcinoma with cisplatin.
@nl
prefLabel
Future perspectives on the treatment of hepatocellular carcinoma with cisplatin.
@ast
Future perspectives on the treatment of hepatocellular carcinoma with cisplatin.
@en
Future perspectives on the treatment of hepatocellular carcinoma with cisplatin.
@nl
P2860
P356
P1476
Future perspectives on the treatment of hepatocellular carcinoma with cisplatin.
@en
P2093
Toru Ishikawa
P2860
P356
10.4254/WJH.V1.I1.8
P577
2009-10-01T00:00:00Z